STOCK TITAN

Fate Therapeutics Inc - FATE STOCK NEWS

Welcome to our dedicated news page for Fate Therapeutics (Ticker: FATE), a resource for investors and traders seeking the latest updates and insights on Fate Therapeutics.

Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Fate Therapeutics's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.

Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Fate Therapeutics's position in the market.

Rhea-AI Summary
Radionetics Oncology, Inc. (RADN) completes $52.5 million Series A financing led by Frazier Life Sciences, 5AM Ventures, and DCVC Bio, bringing total raised to date to $82.5 million. Paul Grayson joins as CEO, bringing expertise in business strategy, oncology, and G-protein coupled receptor biology. Eric Shiozaki, Ph.D., Partner at DCVC Bio, appointed to the board of directors.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.22%
Tags
management
-
Rhea-AI Summary
Fate Therapeutics, Inc. (NASDAQ: FATE) granted a non-qualified stock option to a newly-hired employee to purchase 350,000 shares at an exercise price of $2.28 per share. The option vests over four years, subject to the employee's continuous employment.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
11.19%
Tags
management
-
Rhea-AI Summary
Fate Therapeutics, Inc. (NASDAQ: FATE) reports progress in their iPSC-derived cellular immunotherapies for cancer and autoimmune disorders. Key highlights include the initiation of a Phase 1 study for FT522 ADR-armed, CD19-targeted CAR NK cell program, clearance of IND application for FT825/ONO-8250 CAR T-cell program for solid tumors, and expansion of the iPSC product platform into autoimmunity with FT819 CD19-targeted 1XX CAR T-cell program for systemic lupus erythematosus. The company also reported $350 million in cash, cash equivalents, and investments to support operations into 2H25.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-8.58%
Tags
Rhea-AI Summary
Fate Therapeutics to report Q3 2023 financial results and provide corporate update
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-7.22%
Tags
conferences earnings
-
Rhea-AI Summary
Fate Therapeutics announces participation in investor conferences
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-4.92%
Tags
conferences
-
Rhea-AI Summary
Fate Therapeutics, Inc. (NASDAQ: FATE) reported business highlights and financial results for the second quarter ended June 30, 2023. The company has shown resilience in advancing its innovative programs while reducing expenses, ending 2Q23 with $385 million in cash, cash equivalents, and investments, supporting a runway into 2H25. It has commenced Phase 1 study start-up for FT522 ADR-armed, CD19-targeted CAR NK cell program for B-cell lymphoma and initiated GMP manufacturing of FT825/ONO-8250 under the solid tumor collaboration with ONO Pharmaceutical. The company's FT819 program is advancing in single-dose escalation cohorts for B-cell malignancies, and a 2H23 IND submission is planned for the HER2-targeted CAR T-cell program for solid tumors.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-3.68%
Tags
Rhea-AI Summary
Fate Therapeutics, Inc. (FATE) to Report Q2 2023 Financial Results and Corporate Update
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.68%
Tags
conferences earnings
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.81%
Tags
conferences
-
Rhea-AI Summary
Fate Therapeutics reports business highlights and financial results for Q1 2023. The company is focusing on its CAR NK and CAR T-cell pipeline, with ongoing studies and clinical assessments. They have also completed corporate restructuring and have a strong cash position of $426 million.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.37%
Tags
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.93%
Tags
conferences earnings
Fate Therapeutics Inc

Nasdaq:FATE

FATE Rankings

FATE Stock Data

656.53M
80.71M
1.47%
91.78%
14.49%
Biological Product (except Diagnostic) Manufacturing
Manufacturing
Link
US
San Diego

About FATE

fate therapeutics is applying leading expertise in stem cell biology and conventional drug discovery to develop small molecule and biologic drugs that: 1) activate stem cells in the body to stimulate healing and repair or block cancer growth; and 2) create and differentiate "pharmaceutical grade"​ ips cells to enable their use in drug discovery and development, disease modeling, and eventually personalized cell therapies. the company’s approach has broad therapeutic potential in areas such as regenerative medicine, hematological diseases, metastatic cancer, traumatic injury and degenerative diseases.